ACE2 and viral infectious disease: However, there is no research to confirm that the increased expression of ACE2 can increase the chance of viral infection, so there is no conclusive evidence to confirm that patients with COVID-19 with cardiovascular disease should discontinue RAS inhibitors.30 Kreutz et al stated that a critical review of available evidence does not support a deleterious effect of RAS inhibitors in COVID-19.